Plus   Neg

Tandem Diabetes Care (TNDM) Is Up After FDA Approval

Tandem Diabetes Care (TNDM) announced after the bell Thursday that it received approval fro the FDA for the t:slim X2 Insulin Pump with Basal-IQ technology. The stock is now up 0.89 on 40K shares.

Tandem Diabetes Care traded in a range for the bulk of Thursday's session and closed down by 0.37 at $20.31. The stock pulled back slightly from the highs of the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT